Opportunities to create and expand the range and responsiveness of personalised care services to patients.
Perch News App - Company Name
Opportunities to create and expand the range and responsiveness of personalised care services to patients.
COVID-19 has placed unprecedented pressure on our health system. This brings an added risk to people with long term conditions who need ongoing proactive care to stay well and avoid deterioration.
Bayer has received approval for the use of its oral Factor Xa inhibitor Xarelto® (rivaroxaban) to treat VTE and to prevent VTE recurrence in children from birth to below 18 years after at least 5 days of initial parenteral anticoagulation treatment, including catheter related thrombosis, cerebral vein and sinus thrombosis. The use of a new formulation and strength granules for oral suspension 1mg/ml was also approved.